CN1330142A - Method for exosomatic separation and amplification of filled stem cells between human marrow and funic blood and directional induction toward nerve cells - Google Patents
Method for exosomatic separation and amplification of filled stem cells between human marrow and funic blood and directional induction toward nerve cells Download PDFInfo
- Publication number
- CN1330142A CN1330142A CN01120151A CN01120151A CN1330142A CN 1330142 A CN1330142 A CN 1330142A CN 01120151 A CN01120151 A CN 01120151A CN 01120151 A CN01120151 A CN 01120151A CN 1330142 A CN1330142 A CN 1330142A
- Authority
- CN
- China
- Prior art keywords
- cell
- amplification
- mscs
- marrow
- separation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The percoll with 1.073 of specific weight and the lymphocyte separating liquid with 1.077 of specific weight are respectively used to separate single nuclear cell from marrow and funicle blood. The Mesencult (Stem Cell Co) culture medium is used to purify and amplify the mesenchyme stem cells. The strong antioxidizing agent with proper concentration is used for exosomatic induction of said mesenchyme stem cells for directional differentiation toward nerve cells.
Description
The present invention relates to people's marrow and Cord blood mescenchymal stem cell (mesenchymal stem cells, in-vitro separation amplification MSCs) and the directional induction differentiation of neuralward cell.
Along with organizational project and engineered rise and development, the research of stem cell becomes one of focus of 21 century.In the individual genesis and development process of humans and animals, in embryo and adult tissue, all exist stem cell with height updating ability and multidirectional differentiation potential.But stem cell in-vitro separation, amplification and freezing preservation, and can be induced to differentiate into various kinds of cell and tissue under suitable condition, this provides the ideal model system for inquiring into developmental biology problems such as humans and animals embryo generation, histocyte differentiation, gene expression regulation, has also opened up new way for the cell replacement treatment and the gene therapy (goal gene imports stem cell) of clinical tissue defective disease and heredopathia simultaneously.At present, stem cell tentatively is divided into embryonic stem cell and tissue stem cell two big classes.Though embryonic stem cell has more totipotency, people's embryonic stem cell is studied owing to be subjected to ethics and the restriction of the factors such as difficulty of drawing materials, study less.And tissue stem cell is present in fetus and the various histoorgans of adult, it is extensive relatively to originate, and the further investigation of tissue stem cell do not relate to ethics problem, and infusion is given patient after taking from patient's tissue stem cell directional induction differentiation, does not have immunological rejection.Therefore, tissue stem cell is the main research object of a class of Stem Cell Engineering.
MSCs is the tissue stem cell that the class that receives much attention at present has multidirectional differentiation potential.The bone marrow MSCs of vitro culture has been widely used in research field.Also there is MSCs in report in the Cord blood recently.Cord blood MSCs and bone marrow MSCs are similar, express kinds of surface sign such as SH3, SH4, CD29, CD90 etc.; But do not express the surface marker of hemopoietic stem cell system, as lipopolysaccharides acceptor CD14, CD34 and leukocyte surface antigens c D45 etc.This group cell characteristics is stable, still has multidirectional differentiation potential after continuous passage cultivation and the freezing preservation.Experiment shows that under external specific inductive condition, bone marrow MSCs can be divided into various kinds of cell such as bone, cartilage, fat, tendon, muscle; Cord blood MSCs also has the ability to bone and adipocyte differentiation.This carries out cell therapy for organizational project provides new seed cell, and very big potential applicability in clinical practice is arranged.
The in-vitro separation, purifying, amplification and the directed differentiation that the objective of the invention is to explore marrow and Cord blood MSCs are the condition of neurocyte, provide more competent theoretical foundation and technological method for marrow and Cord blood MSCs are used for the damaging and heredity sacred disease of clinical treatment.
With embodiment the present invention is further elaborated down.
Separation, purifying and the amplification cultivation of embodiment 1. bone marrow MSCs
One, material and method
Aseptic condition is gathered people's marrow of non-disease in the blood system down, with the α that contains 15% foetal calf serum (Hyclone)-5 times of dilutions of MEM nutrient solution, the centrifugal 5min of 400g abandons supernatant and lipid layer, adds α-MEM nutrient solution that 5mL contains 15% foetal calf serum, make cell suspension, the proportion that is added to gently is that the centrifugal 20min of 400g gets interfacial layer on 1.073 the Percoll parting liquid, add 5ml PBS and make single cell suspension, centrifuge washing. with 2.0 * 10
5/ cm
2The density of (T-25 culturing bottle) is inoculated in the Mesencult nutrient solution (StemCell Co.), places 37 ℃, 5%CO
2With cultivate in the incubator of saturated humidity. after cultivating 3d, change substratum, discard not attached cell.When cell of the liquid length to 80% of changing later every 3d merges with 1: 1 0.25% trypsinase and 0.02%EDTA mixed solution had digestive transfer culture (controlling digestion time), with 8.0 * 10 at microscopically
3/ cm
2Density be inoculated in the culturing bottle that goes down to posterity (T-25) and carry out amplification cultivation.
Two, result
MSCs is the spindle shape than homogeneous, and three all left and right sides cell growths reach 80%～90% merges, and each clone is hundreds of approximately to thousands of cells.These passages are cultivated, and the MSCs after going down to posterity reaches fusion about one week, every bottle of average (5.5 ± 0.17) * 10 that obtain, MSCs digestion back that individual layer merges
5Individual cell.5.0 * 10
5Individual former generation adult bone marrow MSCs obtains 7.5 * 10 at amplification in vitro after 15 generations
12Individual cell increases about 1.36 * 10
7Doubly.
Separation, purifying and the amplification cultivation of embodiment 2. Cord blood MSCs
One, material and method
Aseptic condition is gathered down the human cord blood 50-100mL of the non-disease in the blood system of anticoagulant heparin, with the PBS of 0.01M PH7.4 by 1: 1 mixing, by 4: 1 and 0.5% methylcellulose gum mixing, leave standstill the 30min sedimented red cell again.Suct and clear the heart, abandon supernatant, make single cell suspension with PBS, on the lymphocyte separation medium of the proportion 1.077 that is added to, the centrifugal 20min of 400g gets interfacial layer, adds PBS and makes single cell suspension, and centrifuge washing is with 1.0 * 10
6The density of/cm2 (T-25 culturing bottle) is inoculated in the Mesencult nutrient solution (Stem Cell Co.), places 37 ℃, 5%CO
2With cultivate in the incubator of saturated humidity.After one week, changing substratum, discard not attached cell. later every 3-4d changes liquid once.When cell length to 80% merges with 1: 1 0.25% trypsinase and 0.02%EDTA mixed solution had digestive transfer culture (controlling digestion time), with 8.0 * 10 at microscopically
3/ cm
2Density be inoculated in the culturing bottle that goes down to posterity (T-25) and carry out amplification cultivation.
Two, result
The cultured umbilical blood mononuclear cell, full dose is changed liquid after the week, removes not attached cell, and the umbilical cord blood sample mononuclearcell that has is cultivated the back and broken bone like cell occurred, mescenchymal stem cell occurs after the umbilical cord blood sample mononuclearcell that the has cultivation.Broken bone like cell cell space is bigger, rounded, a plurality of nuclears.The mescenchymal stem cell cell space is fusiformis, be dispersed in existence at first, the back formation tens of two weeks is to the clones of a hundreds of cell, rapid propagation along with cell, the back cell growth of three weeks reaches 80%～90% merges, and the about hundreds of of each clone is to several thousand cells, and the MSCs of this moment is the spindle shape than homogeneous, form is similar to bone marrow MSCs, but slightly little than bone marrow MSCs.Every bottle of average (8.25 ± 0.49) * 10 that obtain, Cord blood MSCs digestion back that individual layer merges
5Individual MSCs cultivates these passages 6.6 * 10
5The former generation MSCs of individual Cord blood obtains 9.9 * 10 at amplification in vitro after 10 generations
8Individual cell increases about 1.5 * 10
3Doubly.
The surface antigen characteristic of embodiment 3. marrow and Cord blood MSCs
One, method
Get amplification monobasic marrow and Cord blood MSCs respectively, remove nutrient solution, PBS washes twice, and with 1: 1 0.25% trypsinase and the digestion of 0.02%EDTA mixed solution, making concentration respectively after washing with the PBS that contains 2%BSA was 1.0 * 10
6The single cell suspension of/mL.The bone marrow MSCs single cell suspension adds 3 Eppendof pipe respectively, and each Eppendof pipe adds 500 μ l, manages negative contrast, adds 5 μ lIgG1-FITC and the 5 μ l IgG1-PE monoclonal antibodies of anti-mouse for No. 1; No. 2 pipes add anti-people's 5 μ lCDlla-FITC and 5 μ l CD29-PE monoclonal antibodies; No. 3 pipes add anti-people's 5 μ l CD71-FITC and 5 μ l CD34-PE monoclonal antibodies.Cord blood MSCs single cell suspension adds 6 Eppendof pipe respectively, manages negative contrast, adds 5 μ lIgG1-FITC and the 5 μ l IgG1-PE monoclonal antibodies of anti-mouse respectively for No. 1 and No. 2; All the other four pipes add anti-people's 5 μ l CD71-FITC, 5 μ l CD34-PE, 5 μ lCD11a-FITC, 5 μ l CD29-PE monoclonal antibodies respectively.Incubated at room 20min, flow cytometer detects.
Two, result
Detect discovery through flow cytometer, amplification monobasic marrow and Cord blood MSCs do not express CD34, CD11a, strongly expressed CD29, weak expression CD71.CD34 is the specific surfaces sign of hemopoietic stem cell, and CD11a (LFA-1 α chain) is the lymphocyte sign, and CD29 is the member of integrin family, and CD71 is a TfR.This shows that MSCs is the non-directional ancestral cells that a group that is different from hematopoietic cell in marrow and the Cord blood is in undifferentiated state.
Inducing of the neuralward cell of embodiment 4. marrow and Cord blood MSCs broken up and evaluation
One, method
Get the bone marrow MSCs and 2,5 of amplification in vitro after 2,6,10 generations, the Cord blood MSCs after 8 generations respectively, with 8.0 * 10
3/ cm
2Concentration is inoculated in six orifice plates that are placed with the disinfection cap slide, the preparation cell climbing sheet, every hole adds 2ml Mesencult nutrient solution, when reaching the 60-70% fusion, change the DMEM nutrient solution that contains 20% foetal calf serum (Hyclone) and 3 μ mol/L beta-mercaptoethanols into and induce 24h in advance, PBS (PH7.4) washing then changes the DMEM nutrient solution that contains 2%DMSO and 200 μ mol/L fourth hydroxyanisols (BHA) into and induces.Begin after half an hour to examine under a microscope, observe once every half an hour later on, do not have considerable change up to cellular form.
For marrow and Cord blood MSCs, get the cell climbing sheet of inducing behind 2h, 4h, 6h, the 12h respectively, with reference to Hi stostain
TM-SP (chain enzyme avidin-peroxidase) test kit (Beijing Zhong Shan biotech company) working method is advanced immunohistochemical assay, detect neurofilament protein (neurofilament, NF) and neuronspecific enolase (neuron-specific enolase, NSE).Get the cell climbing sheet of inducing back 6h, 8h simultaneously respectively, use Toluidine blue staining, observe Nissl body.
Two, result
Inducing back 12h to find that original big and flat MSCs cell space shrinks in advance, the irregularity that cell edges becomes has many thin digitations.Induce in advance when finishing, a part of cell cell space has become sub-circular.Tangible morphological change takes place in the 3h inner cell after formally inducing, and the cell cell space further shrinks, and forms circle, the taper of irregularity, trilateral, and the cell that has has a plurality of projections, and sends branch, and whole end has the termination of similar neuronal cell; The projection that has is extended gradually, forms coniform end eventually, and it is prominent to be similar to the neuronic major axis of Golgi I type.Considerable change substantially no longer takes place cellular form behind the 5h, observe to find: bone marrow MSCs has and presents typical neuron phenotype more than 80%, and Cord blood MSCs has about 70% to present typical neuron phenotype.
Immunohistochemical methods is the result show, marrow and Cord blood MSCs induce the back different time all to have NSE and NF to express, and see Table 1.Positive cell is brown.It is painted that the NSE positive cell shows as the diffusivity endochylema, and NF all has expression in nuclear week and projection.
Table 1 marrow and Cord blood MSCs induce the NSE of back different time and NF to express
2h 4h 6h 12hNSE ++ ++ ++ ++ NF ++ ++++++++ +++be dyeing strong positive (dark brown brown), ++ be stained positive (brown)
Toluidine blue staining finds, induces in the kytoplasm of the neuron cell behind 6h and the 8h and exists navy blue bulk or granular Nissl body.
This shows the potential that marrow and Cord blood MSCs all have the neuralward cytodifferentiation.
Claims (2)
1. the method for in-vitro separation, amplification and purifying marrow and Cord blood mescenchymal stem cell, it is characterized in that utilizing the lymphocyte separation medium of the percoll of proportion 1.073 and proportion 1.077 to separate mononuclearcell in marrow and the Cord blood respectively, use Mesencult then
TM(Stem Cell Co.) substratum purifying amplification of mesenchymal stem cells.
2. the external neuralward cell directional of mescenchymal stem cell that separation amplification method as claimed in claim 1 obtains is induced, it is characterized in that adding in the pre-inducing culture 3 μ mol/L beta-mercaptoethanols, add 2%DMS0 and 200 μ mol/L fourth hydroxyanisols (BHA) in the formal inducing culture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011201517A CN1221660C (en) | 2001-07-09 | 2001-07-09 | Method for exosomatic separation and amplification of filled stem cells between human marrow and funic blood and directional induction toward nerve cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011201517A CN1221660C (en) | 2001-07-09 | 2001-07-09 | Method for exosomatic separation and amplification of filled stem cells between human marrow and funic blood and directional induction toward nerve cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1330142A true CN1330142A (en) | 2002-01-09 |
| CN1221660C CN1221660C (en) | 2005-10-05 |
Family
ID=4663937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011201517A Expired - Lifetime CN1221660C (en) | 2001-07-09 | 2001-07-09 | Method for exosomatic separation and amplification of filled stem cells between human marrow and funic blood and directional induction toward nerve cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1221660C (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1948466B (en) * | 2006-11-10 | 2010-05-12 | 中国人民解放军军事医学科学院野战输血研究所 | Reagent box used for preparing bone marrow interstitial stem cell |
| CN1948467B (en) * | 2006-11-10 | 2010-10-06 | 中国人民解放军军事医学科学院野战输血研究所 | Reagent box used for separating bone marrow single nuclear cell |
| CN1878861B (en) * | 2003-11-11 | 2010-10-27 | 韩薰 | Method of isolating and culturing mesenchymal stem cell derived from cryopreserved umbilical cord blood |
| CN101914494A (en) * | 2010-07-27 | 2010-12-15 | 郑州大学 | Separate culture of menstrual blood-derived mesenchymal stem cells and immune adjustment action thereof |
| CN101608174B (en) * | 2009-07-23 | 2012-02-22 | 章毅 | Construction method of human umbilical cord mesenchyma stem cell |
| CN102533644A (en) * | 2011-12-27 | 2012-07-04 | 陆华 | Dimethyl sulfoxide induction method for differentiating human umbilical cord blood mesenchymal stem cells into neuronal cells |
| CN102604890A (en) * | 2012-03-23 | 2012-07-25 | 刘爱兵 | Umbilical cord blood mesenchymal stem cell separation liquid and separation flow |
| CN102816736A (en) * | 2011-06-10 | 2012-12-12 | 张宁坤 | Method for preparing mononuclear cell pre-transplantation state |
| CN102876630A (en) * | 2012-11-05 | 2013-01-16 | 东南大学 | Method for efficiently separating and expanding mesenchymal stem cells in human umbilical cord blood |
| CN103446628A (en) * | 2013-08-20 | 2013-12-18 | 西安交通大学 | Preparation method for tissue engineering nerves of compound seed cells |
| CN115354029A (en) * | 2022-08-16 | 2022-11-18 | 上海长征医院 | Method for producing neural organoid and neural organoid |
-
2001
- 2001-07-09 CN CNB011201517A patent/CN1221660C/en not_active Expired - Lifetime
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1878861B (en) * | 2003-11-11 | 2010-10-27 | 韩薰 | Method of isolating and culturing mesenchymal stem cell derived from cryopreserved umbilical cord blood |
| CN1948467B (en) * | 2006-11-10 | 2010-10-06 | 中国人民解放军军事医学科学院野战输血研究所 | Reagent box used for separating bone marrow single nuclear cell |
| CN1948466B (en) * | 2006-11-10 | 2010-05-12 | 中国人民解放军军事医学科学院野战输血研究所 | Reagent box used for preparing bone marrow interstitial stem cell |
| CN101608174B (en) * | 2009-07-23 | 2012-02-22 | 章毅 | Construction method of human umbilical cord mesenchyma stem cell |
| CN101914494A (en) * | 2010-07-27 | 2010-12-15 | 郑州大学 | Separate culture of menstrual blood-derived mesenchymal stem cells and immune adjustment action thereof |
| CN102816736A (en) * | 2011-06-10 | 2012-12-12 | 张宁坤 | Method for preparing mononuclear cell pre-transplantation state |
| CN102533644A (en) * | 2011-12-27 | 2012-07-04 | 陆华 | Dimethyl sulfoxide induction method for differentiating human umbilical cord blood mesenchymal stem cells into neuronal cells |
| CN102604890A (en) * | 2012-03-23 | 2012-07-25 | 刘爱兵 | Umbilical cord blood mesenchymal stem cell separation liquid and separation flow |
| CN102876630A (en) * | 2012-11-05 | 2013-01-16 | 东南大学 | Method for efficiently separating and expanding mesenchymal stem cells in human umbilical cord blood |
| CN102876630B (en) * | 2012-11-05 | 2015-02-18 | 东南大学 | Method for efficiently separating and expanding mesenchymal stem cells in human umbilical cord blood |
| CN103446628A (en) * | 2013-08-20 | 2013-12-18 | 西安交通大学 | Preparation method for tissue engineering nerves of compound seed cells |
| CN103446628B (en) * | 2013-08-20 | 2015-07-01 | 西安交通大学 | Preparation method for tissue engineering nerves of compound seed cells |
| CN115354029A (en) * | 2022-08-16 | 2022-11-18 | 上海长征医院 | Method for producing neural organoid and neural organoid |
| CN115354029B (en) * | 2022-08-16 | 2023-09-01 | 上海长征医院 | Preparation method of nerve organoid and nerve organoid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1221660C (en) | 2005-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5732011B2 (en) | Identification and isolation of pluripotent cells from non-osteochondral mesenchymal tissue | |
| CN111454893B (en) | Serum-free and xeno-free mesenchymal stem cell culture medium and application thereof | |
| CN112048470B (en) | Method for preparing clinical grade mesenchymal stem cell preparation by using human induced pluripotent stem cells | |
| CN1221660C (en) | Method for exosomatic separation and amplification of filled stem cells between human marrow and funic blood and directional induction toward nerve cells | |
| CN109943526B (en) | A kind of serum-free peptide composition promoting mescenchymal stem cell proliferation | |
| CN111826348A (en) | In-vitro efficient preparation method and application of mesenchymal stem cells derived from human induced pluripotent stem cells | |
| CN106282108A (en) | A kind of spleen mescenchymal stem cell with immunoloregulation function and preparation method and application | |
| CN107418930A (en) | A kind of preparation method purified with amplification human marrow mesenchymal stem cell | |
| CN1778905B (en) | Separating culture and use for fatty mesenchymal dry cell | |
| CN104726401A (en) | Method for improving success rate of umbilical cord blood mesenchymal stem cell culture by using placental mesenchymal stem cells | |
| JP2018023343A (en) | Medium for cell culture, and cell culture method | |
| WO2010013906A9 (en) | Method for separating highly active stem cells from human stem cells and highly active stem cells separated thereby | |
| KR101380561B1 (en) | Equine Amniotic Fluid-Derived Multipotent Stem Cells and Method for Producing the Same | |
| WO2023143006A1 (en) | Kit for inducing ips cells into nk cells and use method thereof | |
| CN102796701A (en) | Method for amplifying human umbilical cord mesenchymal stem cells through in-vitro 3D stent-free suspension cultivation | |
| CN103525761B (en) | Method for separating and culturing animal bone marrow mesenchymal stem cell | |
| CN109735488A (en) | A method of being quickly obtained the mescenchymal stem cell of a large amount of high-purities | |
| CN102250841A (en) | Recoverable immortalized rat bone marrow mesenchyme stem cell as well as preparation method and application thereof | |
| CN109439617A (en) | A kind of stem cell serum-free culture medium and preparation method thereof | |
| Li et al. | Differentiation potential of bone marrow mesenchymal stem cells in duck | |
| WO2018225703A1 (en) | Method for preparing differentiation-induced cells | |
| CN105255821A (en) | Method for culturing periodontal ligament stem cells | |
| KR20190051362A (en) | The method for isolation of stem cells from bone marrow using subfractionation culturing method and proliferation thereof | |
| CN100554415C (en) | The method of monoclonal antibody ZUB4 immunological magnetic bead sorting primary generation human marrow mesenchyme stem cell | |
| Yamane et al. | Embryonic stem cells as a model for studying osteoclast lineage development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20020109 Assignee: SOUTH CHINA CENTER FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE OF ACADEMY OF MILITARY MEDICAL SCIENCES Assignor: Inst. of Field Blood Transfusion, Academy of Military Medical Sciences, PLA Contract record no.: 2015990000123 Denomination of invention: Method for exosomatic separation and amplification of filled stem cells between human marrow and funic blood and directional induction toward nerve cells Granted publication date: 20051005 License type: Exclusive License Record date: 20150324 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20051005 |